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Abstract: Leishmania major (L. major) is a protozoan parasite that causes cutaneous leishmaniasis.
About 12 million people are currently infected with an annual incidence of 1.3 million cases.
The purpose of this study was to synthesize a small library of novel thiophene derivatives,
and evaluate its parasitic activity, and potential mechanism of action (MOA). We developed a
structure–activity relationship (SAR) study of the thiophene molecule 5A. Overall, eight thiophene
derivatives of 5A were synthesized and purified by silica gel column chromatography. Of these eight
analogs, the molecule 5D showed the highest in vitro activity against Leishmania major promastigotes
(EC50 0.09 ± 0.02 µM), with an inhibition of the proliferation of intracellular amastigotes higher
than 75% at only 0.63 µM and an excellent selective index. Moreover, the effect of 5D on L. major
promastigotes was associated with generation of reactive oxygen species (ROS), and in silico docking
studies suggested that 5D may play a role in inhibiting trypanothione reductase. In summary,
the combined SAR study and the in vitro evaluation of 5A derivatives allowed the identification of
the novel molecule 5D, which exhibited potent in vitro anti-leishmanial activity resulting in ROS
production leading to cell death with no significant cytotoxicity towards mammalian cells.
Keywords: thiophene compounds; Leishmania major; cutaneous leishmaniasis; drug screening;
chemotherapy; structure–activity relationship (SAR); in silico docking; reactive oxygen species
1. Introduction
Leishmaniasis is a devastating neglected tropical disease (NTD) [1] caused by the protozoan
parasite of the genus Leishmania. The parasite is transmitted from animals to humans through the
bite of infected females Lutzomyia or Phlebotomus sand flies [2]. Over 20 species and subspecies of
Leishmania infect humans, causing three major clinical forms of the disease: cutaneous (CL), visceral,
and mucocutaneous leishmaniasis [3]. The prevalence of CL, the most common form of leishmaniasis,
is estimated between 0.7 and 1.3 million new annually cases worldwide [4], and it is commonly caused
by Leishmania major (L. major) or L. mexicana. CL presents as singular ulcerative or nodular lesions at the
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bite site that may resolve into scar tissue, often leading to scarring and social stigma [5]. The disease is
present in both the Old World in regions of the Middle East, Africa, Central Western and Easter Europe;
and the New World in regions of Central and South America, and more recently in North America [5].
Currently, there is no preventative or therapeutic human vaccine available against any clinical
manifestation of the disease, and available treatments such as pentavalent antimonials (Glucantime
and Pentostam), liposomal amphotericin B (AmBisome®), and miltefosine (IMPAVIDO®) present
several disadvantages [6]. Pentavalent antimonial treatments are the first line of action, however,
systemic therapy its required for more than 20 days, with toxic side effects including cardiotoxicity and
hepatotoxicity [7,8]. Amphotericin B is highly active, but has extensive toxicity complications (nausea,
vomiting, rigors, fever, hypertension or hypotension, and hypoxia) that usually lead to treatment
interruption; besides, its administration requires hospitalization and its high cost limits its use in
developed countries [5,9]. Miltefosine is the only oral agent against leishmaniasis, however, it presents
several limitations such as embryo-fetal toxicity, fetal death, and its long half-life (150 h) may facilitate
the emergence of drug resistance [10,11]. Thus, these facts clearly emphasize the urgent priority for
the development of novel chemotherapies against leishmaniasis.
Considering the current interest in the search of antileishmanial agents, we previously reported
for the first time that arylalkylamine type-compounds exhibit anti-Leishmania activity with no toxicity
to mammalian cells [12,13]. Toward our medicinal chemistry effort in developing novel compounds
with anti-parasitic activity and drug like properties (e.g., improved solubility, potency, stability and less
or low toxicity), we assessed the antileishmanial activity of a series of novel compounds based on the
thiophene scaffold with pharmaceutical properties: low toxicity, improved potency and solubility [13].
In this context, in the present study, we evaluated nine synthetic thiophene molecules derivatives
against L. major.
We set a goal to design and synthesize a scaffold with antileishmanial activity in a one- or
two-step synthesis using simple and efficient chemical transformations with high yield, high atom
economy and inexpensive starting material. In this study, we focused on the creation of substituted
thiophenes which are considered among the privileged structures in drug discovery [14]. Substituted
thiophenes are known with their various biological activities such as anti-microbial, anti-cancer, and
anti-inflammatory properties [14]. Therefore, the development of novel thiophene compounds with
activity against Leishmania is crucial and urgent, as they may also complement current drugs and
overcome drug resistance.
2. Results
2.1. Synthetic Chemistry
Toward synthesizing the substituted thiophene 5A efficiently, we used the well establish three
components coupling reaction between a ketone, cyanoacetate and elemental sulfur [15] followed
by a simple acylation reaction. The synthesis of 5A is depicted in Figure 1A. After synthesizing
5A, we developed the Structure–Activity Relationship (SAR) of 5A and created eight analogs,
as shown in Figure 1B. The purity of each analog was confirmed by 1H-NMR, 13C-NMR and MS,
and then novel thiophene-like library compounds (Figure 2) were assessed for their potential in vitro
antileishmanial activity.
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Figure 1. (A) Synthesis of thiophene 5A (Ethyl 5,5,7,7-tetramethyl-2-(4-(trifluoromethyl)benzamido)-4,5,6,7-
tetrahydrothieno [2,3-c]pyridine-3-carboxylate). (B) Synthetic route for the creation of thiophene compounds.
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Figure 2. Chemical structures of the nine thiophene compounds.
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2.2. Efficacy and Cytotoxicity of Parent Compound 5A
First, the efficacy of thiophene derivative 5A was evaluated against transgenic L. major
promastigotes expressing firefly luciferase (L. major-luc) as previously described [16,17]. Compound
5A at a range of 0.31–10 µM was incubated with 2 × 106 L. major-luc promastigotes per mL for 72 h at
28 ◦C, and in vitro parasite viability (% survival) was measured by luciferase activity. Compound 5A
displayed an approximate 50% effective concentration (EC50) of 0.34 µM against L. major promastigotes
(Figure 3 and Table 1). Furthermore, we investigated the potential cytotoxicity of 5A by alamarBlue™
Cell Viability Assay (Thermo Fisher Scientific, Waltham, MA, USA) [18] and 5A displayed a selective
index (S.I.) of 30.58 against BALB/c intraperitoneal mouse macrophages (IPΦ), and 51.91 in monkey
kidney cells (LLC-MK2) (Table 1).
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Figure 3. Antiparasitic effect of thiophene derivative 5A. Viability of L. major-luc promastigotes
incubated with 5A at 0.31 to 10 µM for 72 h. Evaluation of intraperitoneal mouse macrophages (IPΦ)
cytotoxicity for 48 h, or monkey kidney cells (LLC-MK2) treated with 5A at concentrations of 0.31 to
40 µM for 72 h. Controls treated with 1% DMSO, or amphotericin B (amp B) at 5 µM.
Table 1. Antiparasitic activity in L. major-luc promastigotes, and cytotoxicity to intraperitoneal mouse
macrophages (IPΦ) or monkey kidney cells (LLC-MK2) of 5A and analogs. EC50 Median effective
concentration. ± values are the estimated EC50 interval. CC50 Median cytotoxic concentration.
± values are the estimated CC50 interval S.I. Selective Index (CC50 mammalian cells)/(EC50 in
L. major-luc promastigotes).
Compound
Leishmania major-luc Mammalian Cells Mammalian Cells
Promastigotes IPΦ LLC-MK2
EC5 (µM) CC50 (µM) [S.I.] CC50 (µM) [S.I.]
5A ~0.3410 ~10.40 [30.50] 17.69± 1.12 [52.85]
5B 5.98 ± 1.72 N/A N/A
5C 4.73 ± 0.69 N/A N/A
5D 0.09± 0.02 27.89± 3.19 [310] >80
5E 0.78± 0.11 16.59± 1.52 [21.27] 80± 4.45 [102.56]
5F >12.50 N/A N/A
5G >12.50 N/A N/A
5H 3.05 ± 0.47 N/A N/A
5I 5.5 ± 1.80 N/A N/A
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2.3. In Vitro Anti-Leishmanial Activity of Thiophene Derivatives and Their Cytotoxicity
Consequently, to lower the toxicity and increase the parasitic activity, eight new thiophene
molecules (Figure 2) were evaluated. First, the thiophene compounds were tested in the presence of
increasing drug concentrations (1.56–12.5 µM), followed by incubation with L. major-luc promastigotes
(2 × 106/mL) for 72 h at 28 ◦C. The experiment was performed using the same conditions as described
for the parent drug 5A. As summarized in Table 1, all eight thiophene molecules showed promising
antileishmanial activity against L. major promastigotes with an EC50 ranging from 0.09 to 6.25 µM
(Figure 4A). However, the best thiophene compounds were 5D (EC50 0.09 ± 0.02 µM) and 5E (EC50
0.78 ± 0.11 µM) (Figure 4B and Table 1).
Consequently, cytotoxicity assays were performed by incubating LLC-MK2 or IPΦ with
compounds. First, 5D or 5E were incubated with 1 × 105 LLC-MK2/mL or 1 × 105 IPΦ/mL for
72 and 48 h, respectively. Interestingly, compound 5D did not display perceptible toxicity against
LLC-MK2 at concentrations up to 80 µM (Figure 4C,D). In the case of IPΦ, 5D exhibited a CC50 value
of 27.89 ± 3.19 µM and an excellent S.I. of 310. As 5E compound CC50 values of 80 ± 4.45 µM in
LLC-MK2 cells and 16.59 ± 1.52 µM in IPΦ, with S.I. values of 102.56 and 21.27, respectively. More
importantly, we determined that both 5D and 5E displayed lower cytotoxicity to mammalian cells and
higher parasitic activity than parent compound 5A (Table 1).
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Figure 4. (A) Antiparasitic effect of the eight thiophene derivatives. Viability of L. major-luc
promastigotes treated with the eight thiophene derivatives at a concentration of 1.56 to 12.5 µM
for 72 h. (B) Evaluation of L. major-luc promastigotes treated with 5D or 5E thiophene derivatives at
lower concentrations (0.005 to 1.56 µM) for 72 h. Controls treated with 1% DMSO, or amphotericin
B (amp B) at 5 µM. (C) Cytotoxicity evaluation of intraperitoneal mouse macrophages (IPΦ) treated
with 5D or 5E thiophene derivatives at concentrations from 0.63 to 20 µM for 48 h. (D) Cytotoxicity
evaluation of monkey kidney cells (LLC-MK2) treated with 5D or 5E thiophene derivatives at a
concentrations from 0.63 to 80 µM for 72 h. Controls treated with 1% DMSO, amp B at 5 µM, or 5% of
hydrogen peroxide (H2O2). Cells were stained with Hoechst 33342 (healthy cell) and Propidium Iodide
(compromised cell).
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2.4. In Vitro Efficacy of Thiophene 5D Against Intracellular Amastigotes
Additionally, efficacy of thiophene compounds 5D and 5E was tested against the infectious
intracellular amastigote form of L. major, by High-Content Imaging Assay (HCIA) on infected
intraperitoneal mouse macrophages. As observed in Figure 5A, in comparison with untreated control
and 1% DMSO, 5D and 5E inhibited the proliferation of the intracellular amastigotes by more than 75%
and 50%, respectively, at a 0.625 µM concentration. Furthermore, as observed in Figure 5B, a reduced
number of infected cells were observed after 5D or 5E treatment (2.5 µM) when compared to control
treated with 1% DMSO.
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Figure 5. (A) High content imaging assay (HCIA) analysis of intraperitoneal mouse macrophages (IPΦ)
infected with L. major-luc amastigotes, followed by treatment with 5D or 5E from 0.63 to 10 µM for
48 h. Controls included untreated, 1% DMSO, amphotericin B (amp B) at 5 µM, or parent drug 5A.
Data are represented as the percentage (%) of infected IPΦ with three or more amastigotes per cell.
Note: Data for 5A at concentration 5 and 10 µM were not generated because 5A was cytotoxic for IPΦ
at such concentration. (B) Representative monochromatic images of infected IPΦ with L. major after
48 h treatment with 5D or 5E at 2.5 µM, amp B (5 µM), or 1% DMSO.
2.5. Molecule 5D Induces ROS in L. major
Based on our previous study [12], it was hypothesized that 5D may induce parasite death through
the production of ROS. Thus, 2 × 106 L. major promastigotes per mL were incubated with 5D (EC50
0.09 ± 0.02 µM). After 24 h, ROS levels were measured by the addition of 10 µM of the cell-permeable
dye H2DCFDA (Thermo Fisher Scientific, Waltham, MA, USA), and fluorescence was monitor for an
additional 7 h using a fluorometer. As expected, ROS levels in 5D treated parasites were 14.5-fold
higher compared to vehicle control 1% DMSO (Figure 6).
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2.6. Docking of 5D on TryR from Leishmania
Next, to determine the possible molecular mechanism responsible for the antileishmanial activity
of 5D, docking studies on TryR from L. infantum (PDB id: 2JK6) were performed. Using Glide Standard
Precision [19] and Extra Precision (XP), we performed Rigid Receptor Docking analysis of control
(Quinacrine Mustard) and 5D. The 3D ligand structures were docked against the best potential binding
site of 2JK6. Glide SP and XP only accounts for the ligand being dynamic however the protein remains
rigid. Docking box coordinates and dimensions remained all at default (20 × 20 × 20 Å). Glide XP
gives an output of a docking score, which was analyzed by the lowest number, or whichever is more
negative to be the highest scoring ligand. The docking results, summarized in Table 2, showed the
control (Quinacrine Mustard) with higher binding affinity than 5D in both SP and XP. However, the
XP docking score did not differ by much, indicating more rigorous docking analysis is needed. Thus,
both ligands were taken to Schrodinger’s Flexible receptor docking.
Table 2. In silico study of 5D and control Quinacrine Mustard.
Receptor Ligand Structure Glide SP (XP) IFD XP (IFD Score)
TryR (2JK6)
5D
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Schrodinger IFD protocol for all IFD jobs was used [20]. The IFD program makes use of both
Glide (for docking) and Prime (for protein structure modeling). The combination of the two software
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packages allows a more accurate ligand binding calculation. We performed the re-docking with Glide
XP for the refined docking results [21]. The IFD data presented in Table 2 show that our lead molecule
5D had a better binding affinity. Docking scores from Rigid Receptor Docking and Flexible Receptor
Docking differed significantly. This is accounted for the protein dynamic movement during
drug binding in IFD. Furthermore, Figure 7A,B presents the IFD binding pocket of the protein–ligand
complex. Figure 7A shows our lead molecule 5D which displays hydrogen bond interactions with SER
1632, ARG 287, VAL 55, and also with CYS 57. Compound 5D also exhibits pi-cation interaction with
residue ARG 287. Quinacrine Mustard interacted with a new set of residues and showed only two
hydrogen bonds between MET 333 and ALA 365 (Figure 7B). The control also formed salt bridges with
ASP 327 as well as GLU 202. pi–pi and pi–cation interaction was also shown between TYR 198 and LYS
60, respectively. These results provided evidence that the possible MOA of 5D may be through the
inhibition of TryR, an essential enzyme to the thiol metabolism of the parasite [22,23], and promising
chemotherapeutic target against leishmaniasis [24].
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3. Discussion
There is an urgent need for new therapeutics that are more effective and less toxic than
conventional treatments used to treat infectious diseases, including leishmaniasis [25]. Thiophenes
derivatives are known for their therapeutic applications and have shown promising results to treat
different types of cancer, degenerative diseases, HIV, and malaria [26–33]. Thus, we evaluated the
anti-leishmania activity and selectivity of nine thiophene derivatives against L. major, and potential
MOA was elucidated for our best candidate, 5D.
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Thiophene derivatives 5A, 5D and 5E exhibited potent parasitic activity against L. major
promastigotes (Table 1). Experimental models involving macrophages are ideal to study leishmaniasis
since they are the major host cell for Leishmania spp. [34]. Thus, our three best candidates were further
evaluated against the most important form of the parasite, intracellular amastigotes, in an in vitro
infection model of murine macrophages. In this case, 5D presented the best anti-leishmanial activity
by decreasing the proliferation of the parasite by 80%.
The in vitro toxicity of 5D and 5E was evaluated towards IPΦ and LCC-MK2 cells. Our best two
compounds were safer for the two cytotoxic models than the reference drug, amphotericin B, which is
already known for its cytotoxic effects [35]. Even though amphotericin B presented similar activity as
5D against promastigotes and amastigotes, this result further supports the application of 5D and 5E as
anti-leishmanial agents. Furthermore, the selectivity presented by 5D was remarkably higher than
the parent compound 5A (10-fold higher), demonstrating the success to increase the anti-leishmanial
activity and reduced cytotoxicity effects when compared to our previously reported arylalkylamine
type-compound [12].
Next, we studied the potential MOA of derivative 5D. ROS can be generated in response to some
drugs, resulting in destruction of cellular macromolecular components inducing cell death by affecting
parasite mitochondrial function [36,37]. Here, we observed that 5D induced ROS production in
L. major promastigotes after 31 h of treatment. The redox homeostasis in Leishmania is achieved
through the activity of several superoxide dismutases, heme peroxidases, as well as of a series
of thiol-containing proteins that directly or indirectly depend on trypanothione reductase [23,38].
In this regard, the trypanothione metabolism is unique to trypanosomatids and its main detoxification
pathway [39]. This pathway protects parasites from oxidative stress and participates in several
cellular processes that are carried out by glutathione in other organisms. Moreover, there are
several trypanothione-dependent pathways that include enzymes such as tryparedoxin peroxidase
(detoxication of hydroperoxide), ascorbate peroxidase (homeostasis of ascorbate), ribonucleotide
reductase (synthesis of DNA precursors), and others [40,41]. With this idea on mind, we decided to
explore in silico docking analysis to assess the possibility of L. major TryR as the target of 5D. Moreover,
our results suggested that TryR interacts with 5D, however we do not exclude the possibility that other
redox metabolism enzymes could be also targeted by compound.
In conclusion, to discover new chemotherapy agents against leishmaniasis, we efficiently
synthetized nine thiophene type-compounds including 5A, following a two-step synthesis from
low-priced commercially available starting materials. We then showed that our novel thiophene
type-compounds possess high in vitro antileishmanial activity. Based on our SAR study, 5D analog
was selected as the most promising lead compound among this library with excellent antiparasitic and
S.I. Furthermore, 5D may act against trypanothione metabolism, followed by the production of ROS in
the parasite; nevertheless, biological studies with recombinant TryR enzyme needs to be performed
to further support this assumption. Overall, 5D represents a potential chemotherapeutic agent for
the treatment of leishmaniasis, and further evaluation in a pre-clinical mouse model of cutaneous
leishmaniasis is currently in progress in our laboratory.
4. Materials and Methods
4.1. General
Unless otherwise noted, all commercial reagents were used as purchased from Aldrich, St. Louis,
MO, USA. All the reactions were monitored by thin-layer chromatography (TLC) that was performed
on silica gel plates GF254. Compounds were visualized under a UV lamp. Flash chromatography
was performed using silica gel (200–300 mesh) with various ratios of Dichloromethane: Methanol
solvents as indicated in the text. Spectroscopy: 1H and 13C-NMR spectra were obtained on a Bruker
DPX 400 MHz. Chemical shifts (δ) are quoted in parts per million (ppm), to the nearest 0.01 ppm
and internally referenced relative to the solvent nuclei. 1H-NMR spectral data are reported with their
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chemical shift in parts per million (ppm). The multiplicity in 1H-NMR is abbreviated as follows: brs:
broad; s: singlet; d: doublet; t: triplet; q: quartet; quint: quintet; sext: sextet; m: multiplet; or as
a combination (e.g., dd, dt, etc.). The coupling constant (J) in hertz, integration and proton count
were determined.
Spectrometer: Liquid chromatography/mass spectra (LC-MS) [+ESI] were taken on double
focusing sector type mass spectrometer HX-110A. Maker JEOL Ltd. Tokyo, Japan (resolution of 10,000
and 10 KV accel. Volt. Ionization method; FAB (Fast Atom Bombardment) used Xe 3 KV energy. Used
Matrix, NBA (m-Nitro benzyl alcohol)). Melting points were measured using a Mel-Temp melting
point apparatus.
4.2. Chemical Synthesis
4.2.1. General Synthetic Procedure 1
Synthesis of the Ethyl 5,5,7,7-tetramethyl-2-(4-(trifluoromethyl) benzamido)-4,5,6,7-tetrahydrothieno
[2,3-c]pyridine-3-carboxylate (5A)
Briefly, the 2,2,6,6-tetramethylpiperidine ketone (1, 1 equivalent) was mixed with 2-cyanoacetate
esters (2, 1 equivalent) and elemental sulfur (1 equivalent) in the presence of diethylamine
(3 equivalents) in ethanol (ETOH) at 60 ◦C for 17 h. The crude was precipitated by adding water
and filtered to provide the desired known 2-aminothiophene intermediate (3) [12]. The latter
was reacted with 4-trifluomethy benzoyl chloride in the presence of diisopropylethylamine in dry
dichloromethane at 0 ◦C for 1 h and then at room temperature for 4 h. The solvent was evaporated
then the crude mixture was purified by flash-column chromatography on silica gel, using a mixture
of solvent of dichloromethane: methanol (DCM: MeOH) at ratios from 100:1 to 50:1, to provide
the desired ethyl 5,5,7,7-tetramethyl-2-(4-(trifluoromethyl)benzamido)-4,5,6,7-tetrahydrothieno
[2,3-c]pyridine-3-carboxylate (5A) as a light brown solid. The purity of 5A was confirmed by 1H-NMR,
13C-NMR, LC/MS and melting point.
4.2.2. General Synthetic Procedure 2
Synthesis of 5,5,7,7-tetramethyl-2-(2-(trifluoromethyl)benzamido)-4,5,6,7-tetrahydrothieno [2,3-c]pyridine-3-
carboxylic acid (5G)
To ethyl 5,5,7,7-tetramethyl-2-(2-(trifluoromethyl)benzamido)-4,5,6,7-tetrahydrothieno [2,3-c]
pyridine-3-carboxylate compound (5B; 1 equiv.) in 1 mL of tetrahydrofuran (THF), was added
5 equiv. of sodium hydroxide (NaOH) in water (1 mL). The mixture was stirred at room
temperature during 17 h. The THF solvent was evaporated then mixture was acidified with
HCl 1M to pH = 4. The protonated acid compound was extracted with ethylacetate (EtOAc)
(3×; 50 mL) then dried under magnesium sulfate (MgSO4), and the solvent was evaporated to
provide the desired 5,5,7,7-tetramethyl-2-(2-(trifluoromethyl)benzamido)-4,5,6,7-tetrahydrothieno
[2,3-c]pyridine-3-carboxylic acid (5G), (Figure 2). The purity of 5G analog was confirmed by 1H-NMR,
13C-NMR, and LC/MS.
Following the general synthetic procedure 1, and in the presence of various substituted benzoyl
chlorides, we created the analogs 5B–5E, and 5H–5I.
Ethyl-5,5,7,7-tetramethyl-2-(2-(trifluoromethyl)benzamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate (5B)
Brown solid, yield 75%, m.p. 181.5–182.5 ◦C. 1H-NMR (400 MHz, CDCl3) δ 11.68 (s, 1H, NHCO),
7.78–7.65 (m, 4H, ArH), 4.32 (q, J = 7.0 Hz, 3H, CH2), 2.70 (s, 2H, CH2), 1.92 (m, 1H, NH), 1.39–1.16
(m, 15H, 5 × CH3). 13C-NMR (101 MHz, CDCl3) δ 166.18, 163.70, 147.33, 135.09, 133.90, 132.18,
130.71, 128.50, 128.32, 126.68, 112.30, 60.61, 51.89, 49.84, 39.53, 34.13, 29.99, 14.00. LC-MS (ESI) for
C22H25F3N2O3S, M + 1 = 455.22.
Molecules 2018, 23, 1626 11 of 16
Ethyl-5,5,7,7-tetramethyl-2-(2-(trifluoromethyl)benzamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylate (5C)
Brown solid, yield 70%, m.p. 132.6–133.6 ◦C. 1H-NMR (400 MHz, CDCl3) δ 11.56 (s, 1H, NHCO),
7.52–7.40 (m, 3H, ArH), 4.10 (q, J = 7.1 Hz, 3H, CH2), 2.53 (s, 2H, CH2), 1.32–1.03 (s, 15H, 5 × CH3).
13C-NMR (101 MHz, CDCl3) δ 166.05, 162.14, 146.93, 138.40, 135.50, 135.04, 130.73, 128.58, 128.43,
128.25, 126.30, 112.53, 60.69, 52.17, 50.17, 39.27, 33.88, 29.71, 13.96. (ESI+, M + 1 = 489.02. LC-MS (ESI)
for C22H24ClF3N2O3S, M + 1 = 489.02.
Ethyl-2-(2-fluoro-3-(trifluoromethyl)benzamido)-5,5,7,7-tetramethyl-4,5,6,7-tetrahydrothieno[2,3-c]-pyridine-3
-carboxylate (5D)
Light brown solid, yield 76%, m.p. 145.4–146.4 ◦C. 1H-NMR (400 MHz, CDCl3) δ 12.40
(d, J = 10.3 Hz, 1H, NHCO), 8.49–8.30 (m, 1H, ArH), 7.83 (dd, J = 10.5, 3.9 Hz, 1H, ArH), 7.45
(t, J = 7.8 Hz, 1H, ArH), 4.42 (q, J = 7.1 Hz, 2H, CH2), 2.74 (s, 2H, CH2), 1.54 (s, 6H, 2 × CH3), 1.42
(t, J = 7.1 Hz, 3H, CH3), 1.23 (t, J = 7.1 Hz, 6H, 2 × CH3). 13C-NMR (101 MHz, CDCl3) δ 165.70, 158.50,
146.67, 136.26, 135.74, 131.23, 129.15, 124.87, 123.48, 121.53, 119.30, 113.11, 60.86, 52.03, 50.01, 39.71,
34.34, 30.23, 14.29. LC-MS (ESI) for C22H24F4N2O3S, M + 1 = 473.05.
Ethyl-2-(4-fluoro-3-(trifluoromethyl)benzamido)-5,5,7,7-tetramethyl-4,5,6,7-tetrahydrothieno[2,3-c]-pyridine
-3-carboxylate (5E)
Light brown solid, yield 66%, m.p. 116.0–117.0 ◦C. 1H-NMR (400 MHz, CDCl3) δ 12.40 (s, 1H,
NHCO), 8.25 (dd, J = 6.4, 1.4 Hz, 1H, ArH), 8.10 (ddd, J = 7.9, 4.1, 2.2 Hz, 1H, ArH), 7.29 (t, J = 9.1 Hz,
1H, ArH), 4.34 (q, J = 7.1 Hz, 2H, CH2), 2.65 (s, 2H, CH2), 1.46 (s, 6H, 2 × CH3), 1.36 (t, J = 7.1 Hz, 3H,
CH3), 1.16 (d, J = 11.3 Hz, 6H, 2 × CH3). 13C-NMR (101 MHz, CDCl3) δ 166.89, 160.81, 148.04, 135.17,
132.73, 128.95, 128.58, 127.43, 119.35, 117.73, 117.51, 112.28, 60.92, 53.37, 52.12, 50.08, 39.57, 34.13, 30.03,
14.18. LC-MS (ESI) for C22H24F4N2O3S, M + 1 = 473.05.
Methyl-2-(4-fluoro-3-(trifluoromethyl)benzamido)-5,5,7,7-tetramethyl-4,5,6,7-tetrahydrothieno[2,3-c]-pyridine3
-carboxylate (5H)
Light brown solid, yield 72%, m.p. 122.0–123.0 ◦C. 1H-NMR (400 MHz, CDCl3) δ 12.45 (s, 1H,
NHCO), 8.32 (s, 1H, ArH), 8.18 (s, 1H, ArH), 7.37 (t, J = 8.0 Hz, 1H, ArH), 3.93 (s, 3H, CH3), 2.71 (s, 2H,
CH2), 1.53 (s, 6H, 2 × CH3), 1.27–1.16 (m, 9H, 3 × CH3).13C-NMR (101 MHz, CDCl3) δ 167.47, 161.06,
160.86, 148.44, 132.84, 132.74, 129.03, 128.46, 127.53, 117.86, 117.64, 112.17, 52.45, 51.80, 50.45, 39.49,
34.13, 29.98 LC-MS (ESI) for C21H22F4N2O3S, M + 1 = 459.07.
Methyl-5,5,7,7-tetramethyl-2-(2-(trifluoromethyl)benzamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3
-carboxylate (5I)
Light brown solid, yield 60%, m.p. 184.2–185.2 ◦C. 1H-NMR (400 MHz, CDCl3) δ1H-NMR
(400 MHz, CDCl3) δ 11.67 (s, 1H, NHCO), 7.78 (d, J = 7.4 Hz, 1H, ArH), 7.66 (dd, J = 10.9, 4.5 Hz, 3H,
ArH), 3.85 (s, 3H, CH3), 2.68 (s, 2H, CH2), 1.52 (s, 6H, 2 × CH3), 1.23 (s, 6H, 2 × CH3). 13C-NMR
(101 MHz, CDCl3) δ 166.90, 164.03, 147.80, 135.24, 134.04, 132.27, 130.83, 128.57, 127.92, 126.90, 126.85,
112.18, 52.18, 51.64, 50.17, 39.59, 34.26, 30.12 LC-MS (ESI) for C21H23F3N2O3S, M + 1 = 441.07.
Following the general synthetic procedure 2, we created the analogs 5F and 5G.
2-(5-chloro-2-(trifluoromethyl)benzamido)-5,5,7,7-tetramethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-
carboxylic acid (5F)
Brown oilesh, yield 51% 1H-NMR (400 MHz, CDCl3) δ 11.69 (s, 1H, NHCO), 7.57–7.44 (m, 3H,
ArH), 2.53 (s, 2H, CH2), 1.32–1.03 (s, 12H, 4 × CH3). 13C-NMR (101 MHz, CDCl3) δ 167.09, 164.14,
161.83, 139.04, 135.50, 135.04, 130.73, 128.58, 128.43, 128.25, 126.30, 112.53, 52.17, 50.17, 39.27, 33.88,
29.71. LC-MS (ESI) for C22H24ClF3N2O3S, M + 1 = 461.03.
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5,5,7,7-tetramethyl-2-(2-(trifluoromethyl)benzamido)-4,5,6,7-tetrahydrothieno[2,3-c]pyridine-3-carboxylic
acid (5G)
Brown oilesh, yield 55%. 1H-NMR (400 MHz, CDCl3) δ 11.70 (s, 1H, NHCO), 7.92–7.62 (m, 4H,
ArH), 2.70 (s, 2H, CH2), 1.39–1.16 (m, 12H, 4 × CH3). 13C-NMR (101 MHz, CDCl3) δ 167.08, 163.70,
162.03, 136.09, 134.01, 132.18, 130.71, 128.50, 128.32, 126.68, 112.30, 51.89, 49.84, 39.53, 34.13, 29.99.
LC-MS (ESI) for C22H25F3N2O3S, M + 1 = 427.02.
4.3. Cell Maintenance
Transgenic L. major promastigotes expressing firefly luciferase (L. major-luc) (Lmj-FV1-LUC-TK
[L. major strain Friedlin {MHOM/JL/80/Friedlin}] were maintain in M199 medium supplemented with
hemin, 10% inactivated fetal bovine serum (iFBS) (Gibco, Thermo Fisher Scientific, Waltham, MA, USA),
and 1% of 10,000 units/mL penicillin and 10 mg/mL streptomycin (Gibco, Thermo Fisher Scientific,
Waltham, MA, USA) as described [42]. Intraperitoneal murine macrophages (IPΦ) were obtained from
BALB/c mice [43]. Monkey kidney epithelial cells (LLC-MK2) (ATCC # CCL-7) (American Type Culture
Collection, Manassas, VA, USA), and IPΦ were cultured in Dulbecco’s Modified Eagle’s Medium
(DMEM), supplemented with 10% iFBS, along with 1% of 10,000 units/mL penicillin and 10 mg/mL
streptomycin. The procedures were performed minimizing the distress and pain for animals following
the NIH guidance and animal protocol (A-201107-1) approved by UTEP’s Institutional Animal Care
and Use Committee (IACUC).
4.4. Luciferase Assay—Viability of Leishmania Major promastigotes
The antiparasitic activity of the 9 thiophene compounds was determined by adding the analogs
together with 2 × 106 L. major-luc promastigotes per mL in 96-well NUNC white microplates (Thermo
Fisher Scientific, Waltham, MA, USA) followed by incubation for 72 h at 28 ◦C. Then, parasite survival
was measured by luciferase activity with the addition of the substrate 5′-fluoroluciferin (ONE-Glo
luciferase assay system; Promega, Madison, WI, USA), using a luminometer (Luminoskan; Thermo
Fisher Scientific, Waltham, MA, USA). The luminescence intensity was a direct measure of the parasite
survival, and 50% effective concentration (EC50) was determined for each drug and summarized in
Table 1.
4.5. Assessment of Thiophene Compound Mammalian Cell Cytotoxicity
The potential cytotoxicity of 5A was tested by alamarBlueTM Cell Viability Assay (Thermo Fisher
Scientific, Waltham, MA, USA) as previously described [18]. Briefly, 1 × 106/mL rhesus monkey
kidney epithelial cells (LLC-MK2), and 1× 106/mL BALB/c IPΦwere seeded in a 96-well clear bottom
black microplate (BD Biosciences, Franklin Lakes, NJ, USA). Cells were incubated in the presence
of increasing drug concentrations for 72 h (LLC-MK2) or 48 h (IPΦ) at 37 ◦C, 5% CO2, followed by
addition of alamarBlueTM. Fluorescence was measured using a fluorometer (Fluoroskan; Thermo
Fisher Scientific, Waltham, MA, USA). Compound 5D or 5E were incubated with 1 × 105 cells/mL
(LLC-MK and IPΦ) for 72 or 48 h, respectively, at 37 ◦C, 5% CO2. After the incubation period, a dilution
of 20:1000 in PBS from a stock at 1 mg/mL of Propidium Iodide (PI) and Hoechst 33342 (Thermo
Scientific, Waltham, MA, USA) were added for survival discrimination as previously described [44].
Analysis was performed by High-Content Imaging Assay (HCIA) using an IN Cell 2000 Analyzer
Bioimaging System (GE Healthcare, Chicago, IL, USA) for LLC-MK2 cells, and BD Pathway 855
High-resolution Bioimager System (BD Biosciences, Franklin Lakes, NJ, USA) for IPΦ. The 50%
cytotoxic concentration (CC50) and selective index (S.I.) was determined and summarized in Table 1.
4.6. High-Content Imaging Assay—Proliferation Experiments
BALB/c IPΦ were acquired and seeded at a density of 1 × 105 cells/mL for 2 h at 37 ◦C, 5% CO2.
After adherence, IPΦwere infected with 1× 106/mL metacyclic promastigotes of L. major-luc, at a ratio
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of 10:1 parasites per macrophage. Subsequently, infected IPΦ were incubated with derivatives 5A, 5D
and 5E at increasing concentrations (0.625 to 10 µM) for 48 h treatment. Afterwards, cells were fixed
with 4% paraformaldehyde, and stained with (1.25:100) Alexa Fluor™ 488 Phalloidin (Thermo Fisher
Scientific, Waltham, MA, USA) and (1:1000) DAPI (Sigma Aldrich, St. Louis, MO, USA). Then, the
numbers of infected cells and amastigotes were determined by HCIA using an IN Cell 2000 Analyzer
Bioimaging System (GE Healthcare, Chicago, IL, USA). Parameters were set for the excitation and
emission spectra of Alexa Fluor™ 488 Phalloidin and DAPI, and a constraint of 3 or more parasites per
macrophage was set as previously reported [44,45].
4.7. Measurement of Reactive Oxygen Species Levels
L. major promastigotes (2 × 106 cells/mL) were incubated for 24 h with 5D (EC50 0.90 µM) in a
96-well clear bottom black microplate (BD Biosciences, Franklin Lakes, NJ, USA). Controls treated with
1% DMSO, 100 µM of hydrogen peroxide (H2O2) as positive control, or M199 medium. After incubation
period, 10 µM of H2DCFDA (Thermo Fischer Scientific, Waltham, MA, USA) (H2DCFDA/DMSO,
1 mg/mL) was added per well followed by 20 min of incubation at 37 ◦C. Fluorescence was measured
for an additional 7 h using a fluorometer (Fluoroskan; Thermo Fisher Scientific, Waltham, MA, USA) at
527 nm using an excitation wavelength of 485. For all measurements, basal fluorescence was subtracted.
All graphs, EC50 and CC50 values were produced using Graph Pad Prism 7 Software (GraphPad
Software, Inc., La Jolla, CA, USA).
4.8. Docking Studies—Pre-Docking Preparation
The structure of trypanothione reductase bound to Flavin adenine dinucleotide (PDB ID: 2JK6) [46]
were obtained from the Protein Data Bank. The Protein Preparation Wizard in Maestro was used
to minimize the protein structure, add hydrogens and charges, and find any missing residues.
The two-dimensional structures of 5D and Quinacrine Mustard, a recently experimentally approved
drug as a control, were drawn using the molecular structure editor ChemDraw Software (PerkinElmer,
Waltham, MA, USA) and processed by LigPrep Schrödinger (Schrödinger, LLC., New York, NY, USA)
to generate the 3D structures.
4.9. Binding Site Analysis
Maestro’s SiteMap tool (Schrödinger, LLC., New York, NY, USA) was used to predict the likely
binding sites of trypanothione reductase. The SiteMap tool uses a series of algorithm that generates
a map of hydrophobic and hydrophilic surfaces on the protein surface [47]. Hydrophilic surface
maps are divided into donor, acceptor, and metal-binding regions. Five potential binding sites were
identified with at least 15 site points. However, the top SiteMap was chosen to be the receptor grid.
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